Key facts
- Luminary Therapeutics’s last known valuation is $59.0M (Apr 2025).
- It has raised $24.2M across 6 recorded rounds; the latest was Seed Round ($1.4M) in Oct 2025.
- Notable investors include National Institutes of Health, Lateral Capital Management, Cure Xchange Challenge, 701 Fund, Cure Experience Services — 7 tracked in total.
- Luminary Therapeutics has filed 7 Form Ds with the SEC since 2019, most recently Jan 2025 ($5.2M sold to 49 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 6 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Luminary Therapeutics
Funding rounds
6 roundsAbout Luminary Therapeutics
Developer a cell therapy platform designed for cancer and autoimmune diseases. The company's platform creates an engine that completes novel and early therapeutic discovery with the help of a pipeline for B-cell malignancies, autoimmune disorders, and solid tumors autoimmune disorders, enabling doctors to eliminate viral-based cell therapy issues.
- Sector
- Healthcare
- HQ
- Minneapolis, MN, United States
- Founded
- 2019
- Employees
- 8
- Website
- luminarytx.com/
- Ownership
- Privately Held (backing)
Luminary Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Luminary Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Luminary Therapeutics in its N-PORT filings yet. We sweep new filings monthly.